AHA 23 - Dr Naima Maqsood, CardioNerds ambassador  (Temple University Hospital, US) interviews Dr Christian Ruff (Brigham and Women's Hospital, US) on the late-breaking findings from the AZALEA-TIMI 71 randomized trial (Anthos Theraputics, Inc). 

AZALEA-TIMI 71 aimed to evaluate the bleeding profile of abelacimab as compared to rivaroxaban in patients with atrial fibrillation who are at moderate to high risk of stroke. 1200 patients were enrolled in the trial, who were randomized to receive either the experimental group, or the active comparator group. The experimental arm was split into two treatment groups, where one group received a middle dose of abelacimab, and another received a high dose, both administered subcutaneously once per month. In the active comparator group, 20mg rivaroxaban was taken once per day. 

Results showed a potent inhibition of factor XI, with over 95% inhibition over the dosing interval. A ≥2/3 reduction in bleeding as compared to rivaroxaban was observed in patients treated with abelacimab, with reduced major or clinically relevant non-major bleeding, major bleeding and major GI bleeding. 

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia. 

Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.